Journal of Alzheimer’s Disease Welcomes New Co-Editor-in-Chief Paula I. Moreira, PhD

8 January 2024

Amsterdam, the Netherlands – The Journal of Alzheimer’s Disease (JAD), published by IOS Press, is pleased to announce the appointment of new co-Editor-in-Chief, Paula I. Moreira, PhD. Dr. Moreira joins Editor-in-Chief George Perry, PhD, and an eminent international editorial board who are dedicated to the continuing success of the world’s leading journal in Alzheimer’s research and treatment.

Dr. Moreira is an Associate Professor of Physiology at the Faculty of Medicine, University of Coimbra and leads the MitoBD (Mitochondria in Brain Disorders) research group at the Center for Neuroscience and Cell Biology, University of Coimbra (CNC-UC), Portugal. Dr. Moreira’s research group is mainly interested in elucidating the critical role of mitochondria (energy, homeostasis, and signals) in brain changes associated with metabolic and neurodegenerative diseases, with a special emphasis on Alzheimer's disease. Her research group is also interested in exploring the preventive and therapeutic potential of pharmacological and nonpharmacological strategies, such as mitochondrial modulators and hypoxic (pre)conditioning. 

Dr. Moreira was the recipient of the Stimulus to Research prize in 2003, supported by the Calouste Gulbenkian Foundation, the L’Oréal for Women in Science Award in 2008, supported by L’Oréal Portugal/UNESCO/FCT, and in 2023, the RFS Award from the Science for Antioxidants & Redox Signaling journal, supported by Mary Ann Liebert, Inc. in collaboration with the Rosalind Franklin Society.

Paula Moreira has been an Associate Editor of JAD since 2004, served as a Regional Editor in 2016 and as Deputy Editor from 2017 to 2023. She has published and reviewed many articles for the journal. She joins Editor-in-Chief George Perry to help further consolidate JAD’s already eminent position as a reference journal in the field of Alzheimer's disease and related dementia. 

“I am committed to support the growth of JAD as a top repository of cutting-edge basic, translational, and clinical research,” commented Dr. Moreira. “The accelerated pace at which new knowledge about Alzheimer’s disease pathophysiology builds up, together with the rapid development of diagnostic and treatment strategies, require an effective and speedy knowledge transfer between the scientific and clinical communities. JAD, as the leading journal in this field, is the primary ‘voice’ of the most innovative advancements in Alzheimer’s disease.”

George Perry, Editor-in-Chief, Journal of Alzheimer's Disease, and Semmes Foundation Distinguished University Chair in Neurobiology at The University of Texas at San Antonio.said, “We are honored by Dr. Moreira’s acceptance of this new role and the leadership she brings to JAD. She is a leading scientist with years of innovative insights, mentorship, and collegiality focused on solving the puzzle of Alzheimer’s disease.” 

#  #  #



The Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 4.0 according to Journal Citation Reports™ (Clarivate, 2023). 


IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement.